Selank

Origin and Structure

Selank is a synthetic heptapeptide with the amino-acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues (Thr-Lys-Pro-Arg) correspond to tuftsin, a tetrapeptide fragment of the immunoglobulin G heavy chain that occurs naturally and has been studied since the 1970s for its immunomodulatory activity. The C-terminal Pro-Gly-Pro tail is a stabilizing motif — the same tripeptide that extends the half-life of Semax — that resists peptidase cleavage and allows intranasal delivery.

Selank was developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, within the same research program that produced Semax. It was registered as a medicine in Russia in the early 2000s for generalized anxiety disorder and asthenic syndromes, where it is prescribed primarily as an alternative to benzodiazepines for patients in whom sedation, dependence, or cognitive blunting are particular concerns.

Mechanism of Action

Selank's pharmacology is distinct from conventional anxiolytics. The most frequently cited mechanistic threads:

• GABAergic modulation without direct receptor binding. Selank appears to increase GABA-A receptor expression and to modulate GABAergic tone indirectly. Unlike benzodiazepines, it does not bind the benzodiazepine site on the GABA-A receptor and does not produce classical sedation, tolerance, or dependence patterns.
• Enkephalin-degrading enzyme inhibition. Selank inhibits enkephalinase, raising endogenous enkephalin and extending the half-life of the body's own opioid-related signaling — a mechanism shared with Semax and relevant to stress-buffering effects.
• Serotonergic and monoaminergic effects. Russian research has reported increased serotonin metabolism in limbic structures and modulation of BDNF expression, parallel to (though less pronounced than) Semax's neurotrophic effects.
• Immunomodulation. The tuftsin component retains modest immunomodulatory activity, and some Russian literature has emphasized effects on cytokine balance and interferon response.

Clinical Evidence

Like Semax, most of the clinical literature on Selank is published in Russian-language journals, with partial English translation. The evidence base clusters into:

• Generalized anxiety disorder. Several Russian trials, including comparative studies against medazepam, have reported anxiolytic efficacy comparable to benzodiazepines without the sedation, cognitive impairment, or withdrawal-phenomenon profile.
• Adjunctive use with benzodiazepine taper. A notable use case in Russian practice is concurrent administration during benzodiazepine discontinuation, where small studies suggest Selank eases withdrawal symptoms.
• Asthenic and stress-related disorders. Broader indications for post-stress cognitive complaints, with smaller effect sizes reported on attention and working-memory tasks.

The same caveats that apply to Semax's evidence base apply here: methodology varies, independent international replication is limited, and the picture available to English-language readers is incomplete. What is notable is that Selank has been in continuous clinical use for approximately two decades in Russia without significant safety signals — a form of real-world evidence that, while unconventional, is not trivial.

Practical Considerations

Selank is administered intranasally, typically as a 0.15% aqueous solution delivering 300–900 mcg per day divided across two or three doses. Its short half-life (roughly 30 minutes in plasma, though CNS effects persist longer via downstream signaling) suits acute-anxiety use rather than continuous dosing. Onset of subjective effect is generally reported within 15–30 minutes of administration.

Selank is frequently discussed alongside Semax — both are Russian-developed nasal neuropeptides with C-terminal Pro-Gly-Pro stabilization — though they target different endpoints: Semax is positioned more toward cognitive and neuroprotective applications, Selank toward anxiolytic and stress-buffering use. The two are sometimes used sequentially or concurrently in nootropic-peptide protocols, though no formal trial data supports combination use.

Regulatory Status and Safety

Selank is not approved by the FDA, EMA, or most major Western regulators. It remains a registered medicine in Russia and a research chemical elsewhere. The side-effect profile reported across Russian clinical use is mild — occasional nasal irritation, mild drowsiness or paradoxical agitation in a minority, and rare transient dyspepsia. Notably absent from the profile are the sedation, dependence, rebound anxiety, and cognitive impairment associated with benzodiazepines.

The Bottom Line

Selank is one of the few anxiolytic compounds in this library with meaningful real-world human clinical exposure, concentrated in a single national healthcare system. It represents a mechanistically distinct approach to anxiety — GABAergic modulation without direct receptor binding, combined with enkephalinase inhibition — that deserves more international study than it has received. For anyone evaluating nootropic or anxiolytic peptides, Selank and Semax together form the core of the Russian neuropeptide tradition.